<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-XPD5ED2A</identifier><date>2017</date><creator>Ocvirk, Janja</creator><relation>documents/doc/X/URN_NBN_SI_doc-XPD5ED2A_001.pdf</relation><relation>documents/doc/X/URN_NBN_SI_doc-XPD5ED2A_001.txt</relation><format format_type="issue">2</format><format format_type="volume">21</format><format format_type="type">article</format><format format_type="extent">str. 22-25</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">2841467</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-XPD5ED2A</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">anti-PD-1 protitelesa</subject><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="slv">zaviralci receptorjev</subject><title>Anti PD-1 protitelesa</title><title>Anti-PD-1 antibodies</title><title>uporaba, delovanje, neželeni učinki</title><title>use, action, side effects</title></Record>